Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports that drug repurposing for COVID-19 has had mixed results, with success for some drugs but a lack of clinical efficacy for others, highlighting the need for improved preclinical profiling and a standardized drug development platform for future antiviral treatments.

JAK inhibitors and platelet-rich plasma show promise for treating alopecia areata.

This case report highlights lichen planus pigmentosus in a 60-year-old man, which was linked to previously undetected hepatitis C infection and liver cirrhosis, suggesting a need for hepatitis C testing in patients with similar dermatological manifestations.

This study developed PiSCES biosignatures that distinguished alopecia areata patients from controls, revealing enhanced basal TCR signaling and a potential disease-specific signaling network signature.

This study found that manipulating Wnt signaling pathways in cutaneous wounds can induce skin structures resembling regeneration, suggesting a potential role for Wnt signals in restoring skin architecture during wound healing.

This study suggests that diffuse alopecia areata initially involves an intense inflammatory attack during the anagen phase, progressing through different hair cycle stages with specific shedding patterns.

In this study, the authors compared trichoscopy findings for different forms of diffuse non-cicatricial alopecia in females and suggested that trichoscopy might often replace the need for histopathological confirmation, reserving biopsies for more uncertain cases.

Combining conventional and integrative treatments can help reduce hair loss and improve hair growth in women with androgenic alopecia.

This source explains that unlike genetic hormonal alopecia, alopecia areata is associated with inflammatory factors and may also involve psychological and genetic contributions.

This study found that diphencyprone is an effective and safe treatment for extensive alopecia areata, especially with long-term therapy and maintenance to reduce relapse risk.

This study reports that topical immunotherapy with SADBE and DPCP is the most effective short-term treatment for hair regrowth in children with severe alopecia areata compared to other treatments.

In this observational study, researchers found that mini-pulse oral corticosteroids effectively reduced hair loss in alopecia areata patients who did not respond to topical therapies, though early-onset patients and those with hypothyroidism were less likely to benefit.

DHEA therapy improves pubic hair growth and psychological well-being in young females with central adrenal insufficiency.

This study found that dauricine, a natural compound, may inhibit cell growth and enhance apoptosis in neuroblastoma and glioblastoma by blocking the Oct4/Shh pathway and AKT/β-catenin signaling.

This study found that topical immunotherapy affects angiogenesis and immune cell ratios in the scalp, potentially offering insights into the mechanisms underlying alopecia areata.

This study found that dapsone treatment for severe alopecia areata resulted in hair regrowth rates similar to spontaneous recovery, making it significantly less effective than topical immunotherapy.

DHEA treatment helps grow pubic hair and boosts mood in girls with adrenal issues.

This study evaluated the use of oral DHEA for treating atrichia pubis and psychological distress in young females with central adrenal insufficiency but reports no new results.

This study found that precision 40Hz gamma-transcranial alternating current stimulation significantly improved negative and cognitive symptoms in patients with schizophrenia compared to a sham group, suggesting promising potential for this neuromodulation technique in treating these symptoms.

DHEA therapy improved pubic hair growth and psychological well-being in young females with adrenal insufficiency.

This study found that autologous γdTregs displayed significant protective effects on alopecia areata-affected human scalp hair follicles in both ex vivo and in vivo settings, suggesting potential for future cell-based therapy.

This review examines topical immunotherapy for severe alopecia areata, noting that diphencyprone and squaric acid dibutylester are non-mutagenic options with similar efficacy but different practical considerations, and reports no new clinical results.

This study found that hair regrowth occurred in 72.2% of alopecia areata patients treated with diphencyprone, with disease extent at baseline and duration affecting outcomes.

Mini pulse corticosteroid therapy with oral dexamethasone is effective and has fewer side effects for treating extensive alopecia areata.

In this case report, a 9-year-old boy with diffuse alopecia areata showed improvement with topical diphencyprone immunotherapy, suggesting it as a safe and effective treatment option in pediatric cases of alopecia areata resistant to other therapies.

This study found that immunotherapy with DNCB or DPCP showed better therapeutic effects than intralesional triamcinolone acetonide for patients with bald areas greater than 50 cm², including alopecia totalis and universalis.

This study found hair regrowth in the majority of AA-affected mice and rats treated with diphencyprone, suggesting its potential utility for understanding human alopecia areata and the drug's therapeutic action.

Intramuscular triamcinolone and pulse therapy with oral predonine are effective for alopecia areata with manageable side effects, but better relapse prevention is needed.

Farudodstat may effectively treat alopecia areata without harming hair follicles.

This study found that Diphenylcyclopropenone (DCP) was effective for treating extensive alopecia areata in Thai patients, although a high relapse rate suggests maintenance therapy might be necessary.